NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis $8.98 -0.60 (-6.26%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$8.99 +0.01 (+0.11%) As of 10/2/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Benitec Biopharma Stock (NASDAQ:BNTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Benitec Biopharma alerts:Sign Up Key Stats Today's Range$8.92▼$9.8850-Day Range$8.98▼$13.7852-Week Range$8.92▼$16.76Volume135,137 shsAverage Volume154,743 shsMarket Capitalization$313.22 millionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingModerate Buy Company Overview Benitec Biopharma Limited (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines for chronic and potentially life-threatening diseases. The company’s work is based on DNA-directed RNA interference (ddRNAi), a gene-silencing technology designed to produce sustained suppression of disease-causing genes within targeted cells. Benitec’s lead investigational product is BB-301, an adeno-associated virus gene therapy being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive difficulty swallowing and weakness of the eyelid and throat muscles. BB-301 is designed to silence the mutated PABPN1 gene associated with OPMD while supporting production of a functional version of the gene. Founded in Australia in 1995, Benitec has developed its technology through research, licensing, and clinical-development activities and now operates as a U.S.-based biotechnology company. Its activities are focused primarily on advancing its gene-therapy pipeline through clinical studies and regulatory development rather than marketing commercial products.AI Generated. May Contain Errors. Read More Benitec Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreBNTC MarketRank™: Benitec Biopharma scored higher than 41% of companies evaluated by MarketBeat, and ranked 622nd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBenitec Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBenitec Biopharma has a consensus price target of $24.00, representing about 167.3% upside from its current price of $8.98.Amount of Analyst CoverageBenitec Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Benitec Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Benitec Biopharma are expected to decrease in the coming year, from ($1.31) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Benitec Biopharma is -9.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Benitec Biopharma is -9.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Benitec Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.58% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 19.97, which indicates bearish sentiment.Change versus previous monthShort interest in Benitec Biopharma has recently decreased by 1.28%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.62 News SentimentBenitec Biopharma has a news sentiment score of -0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Benitec Biopharma this week, compared to 3 articles on an average week.Search Interest2 people have searched for BNTC on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Benitec Biopharma's insider trading history. Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNTC Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)September 16, 2026 | theglobeandmail.comWedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform RatingSeptember 15, 2026 | finance.yahoo.comWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.October 4 at 1:00 AM | Paradigm Press (Ad)Benitec Biopharma Files $200 Million Shelf RegistrationSeptember 15, 2026 | finance.yahoo.comBenitec Biopharma FY26 Net Loss Widens; BB-301 Interim Data Due In OctoberSeptember 15, 2026 | rttnews.comBenitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational UpdateSeptember 14, 2026 | globenewswire.comBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational UpdateMay 14, 2026 | globenewswire.comBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the ...April 29, 2026 | markets.businessinsider.comSee More Headlines BNTC Stock Analysis - Frequently Asked Questions How have BNTC shares performed this year? Benitec Biopharma's stock was trading at $13.47 at the beginning of 2026. Since then, BNTC shares have decreased by 33.3% and is now trading at $8.98. How were Benitec Biopharma's earnings last quarter? Benitec Biopharma Limited (NASDAQ:BNTC) issued its earnings results on Monday, September, 14th. The biotechnology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.00. When did Benitec Biopharma's stock split? Benitec Biopharma's stock reverse split before market open on Wednesday, July 26th 2023.The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), ADMA Biologics (ADMA), BioLineRx (BLRX), Exelixis (EXEL) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings9/14/2026Today10/04/2026Next Earnings (Estimated)11/13/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, BNTC's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BNTC CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees24Year Founded2001Price Target and Rating Average Price Target for Benitec Biopharma$24.00 High Price Target$32.00 Low Price Target$17.00 Potential Upside/Downside+167.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-28.41% Return on Assets-27.76% Debt Debt-to-Equity RatioN/A Current Ratio34.00 Quick Ratio34.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.15 per share Price / Book1.74Miscellaneous Outstanding Shares34,880,000Free Float33,209,000Market Cap$313.22 million OptionableNo Data Beta0.25 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BNTC) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
